Good morning. I am Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis Pharma, and I will be presiding over today's virtual meeting of stockholders. On behalf of our company, I want to welcome you to our 2026 annual meeting of stockholders, which is now formally called to order. We're very pleased to have each of you in attendance at today's virtual meeting. Let me begin by introducing the directors of the company in attendance by means of remote communication. With us today are Ken Hoberman, Matt Kaplan, James Oliviero, and Dr. Juan Sanchez. Also virtually present here today is Abhiram Dalal of Kesselman & Kesselman, a member firm of PwC, our independent auditors for the year ending December 31st, 2025.
Matt Mamak of Alston & Bird LLP, our legal counsel, who will serve as secretary of the meeting, and Chandi Neubauer-Jackson of CT Hagberg, who will serve as the inspector of elections for the meeting. Our order of business this morning will be to introduce and act upon the matters of business described in the proxy statement for this 2026 annual meeting of stockholders, collect the votes, and then receive a report from the inspector of elections on the voting results. This brings us to the determination of a quorum. Our bylaws and Delaware law provide that the presence, in person or by proxy, of a majority of the shares of stock issued and outstanding on the record date constitutes a quorum. Mrs. Jackson, do we have a quorum?
Yes, we do. A majority of the shares of stock issued and outstanding as of the record date, April 13th, 2026, are represented at the meeting.
Thank you, Mrs. Jackson. We will proceed with voting on the matters described in the proxy statement to be acted upon at this meeting. All stockholders of record as of April 13th, 2026, are entitled to vote at this virtual meeting. Any such stockholder who has not voted by proxy and now wants to vote, or has previously voted by proxy and now wants to change that vote may do so now by clicking on the voting button on the web portal and following the instructions there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. The polls are now open for voting. There are two items of business to be voted on by the stockholders.
The first item is the election of myself, Ron Bentsur, as director, to hold office until the annual meeting in 2029, or until a respective successor has been elected and qualified, or until I resign or removed from office. The second item is the ratification of the appointment of Kesselman & Kesselman as the company's independent registered public accounting firm for the 2026 fiscal year. I will now pause for 15 seconds. There is no other business on today's agenda, we will proceed with the balloting on the foregoing items of business. I now declare the polls closed. I want to thank everyone for your participation. I will now ask the inspector of elections to report on the preliminary voting results.
Mr. Bentsur, the preliminary results are as follows. Number one, the nominee for director has been approved. Number two, the ratification of the appointment of Kesselman & Kesselman as the company's independent registered public accounting firm for the 2026 fiscal year has been approved.
Thank you very much. That completes our formal business for today. The complete voting results will be contained in a Form 8-K that will be filed with the SEC within four business days following this meeting. The Form 8-K will also be available on our website promptly after it is filed. I now declare the 2026 annual meeting of stockholders adjourned. On behalf of our company, I would like to thank each of you for your attendance and your support of Nuvectis Pharma. Have a good day. Thank you.
This concludes the meeting. You may now disconnect.